Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 5/20 | 0.63 |
| ▸ | GSK3A | P49840 | 5/20 | 0.63 |
| ▸ | GSK3B | P49841 | 5/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.63 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.63 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.63 |
| ▸ | ICAM1 | P05362 | 9/20 | 0.57 |
| ▸ | SELE | P16581 | 9/20 | 0.57 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.57 |
| ▸ | CCNC | P24863 | 3/20 | 0.57 |
| ▸ | CDK8 | P49336 | 3/20 | 0.57 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.46 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.46 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.46 |
| ▸ | PLK4 | O00444 | 4/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 4/20 | 0.45 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.45 |
| ▸ | CDK1 | P06493 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30744198 | 1.00 | CSNK1D (0.63) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL31059946 | 0.86 | ICAM1 (0.56) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL5555028 | 0.85 | CSNK1D (0.48) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL7060300 | 0.84 | ICAM1 (0.57) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL660382 | 0.83 | GSK3A (0.60) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL5550593 | 0.83 | ICAM1 (0.56) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL29831616 | 0.83 | ICAM1 (0.56) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL660279 | 0.83 | ICAM1 (0.66) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL5550652 | 0.83 | ICAM1 (0.56) | CSNK1DGSK3AGSK3BDYRK1AAURKB | |
| SCHEMBL30744193 | 0.83 | ICAM1 (0.66) | CSNK1DGSK3AGSK3BDYRK1AAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979675-A | Small-molecule sulfur-containing heterocyclic compound | 维眸生物科技（上海）有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2021115495-A1 | SMALL-MOLECULE SULFUR-CONTAINING HETEROCYCLIC COMPOUND | 维眸生物科技（上海）有限公司 | 2021-06-17 | — | — | WO | disclosed |
| WO-2021115495-A1 | SMALL-MOLECULE SULFUR-CONTAINING HETEROCYCLIC COMPOUND | 维眸生物科技（上海）有限公司 | 2021-06-17 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-1753428-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | Abbott Laboratories (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABBOTT LABORATORIES | 2006-04-06 | — | — | US | disclosed |
| WO-2005110410-A2 | KINASE INHIBITORS AS THERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074102-A1 | Kinase inhibitors as therapeutic agents | ABL1, MAP3K19, MAP3K20 | CSNK1D 151/4885GSK3A 453/4885GSK3B 462/4885 |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | CSNK1D 734/4885GSK3A 581/4885GSK3B 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.